Home > Insider Trading > Filing (0001578563-17-000011)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1560241	G1 Therapeutics Inc.	GTHX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1033409	N Fredric Eshelman	C/O G1 Therapeutics, Inc. 79 T.w. Alexander Drive Research Triangle Park NC 27709		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-13	250,000	$19.73	250,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,439,151	Indirect	See Footnote

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (right to buy)	$15.55		2027-07-11	20,000	20,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2027-07-11	20,000	20,000	Direct

Footnotes

Eshelman Ventures, LLC is the record holder of the securities. Dr. Fredric Eshelman is the founder and principal of Eshelman Ventures, LLC and may be deemed to beneficially own the securities held by Eshelman Ventures, LLC. Dr. Eshelman disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The stock option will vest in thirty-six monthly installments at the end of each successive month following July 11, 2017, subject to the Reporting Person's continued service as a director.